001     141418
005     20240229105127.0
024 7 _ |a 10.1002/ijc.31650
|2 doi
024 7 _ |a pmid:29971779
|2 pmid
024 7 _ |a pmc:PMC6220964
|2 pmc
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:44473505
|2 altmetric
037 _ _ |a DKFZ-2018-01924
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Lin, Crystal
|b 0
245 _ _ |a Pre-diagnostic circulating insulin-like growth factor-I and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition.
260 _ _ |a Bognor Regis
|c 2018
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1542807962_13986
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Previous in vitro and case-control studies have found an association between the insulin-like growth factor (IGF)-axis and bladder cancer risk. Circulating concentrations of IGF-I have also been found to be associated with an increased risk of several cancer types; however, the relationship between pre-diagnostic circulating IGF-I concentrations and bladder cancer has never been studied prospectively. We investigated the association of pre-diagnostic plasma concentrations of IGF-I with risk of overall bladder cancer and urothelial cell carcinoma (UCC) in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 843 men and women diagnosed with bladder cancer between 1992 and 2005 were matched with 843 controls by recruitment centre, sex, age at recruitment, date of blood collection, duration of follow-up, time of day and fasting status at blood collection using an incidence density sampling protocol. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression with adjustment for smoking status. No association was found between pre-diagnostic circulating IGF-I concentration and overall bladder cancer risk (adjusted OR for highest versus lowest fourth: 0.91, 95% CI: 0.66-1.24, ptrend = 0.40) or UCC (n of cases = 776; 0.91, 0.65-1.26, ptrend = 0.40). There was no significant evidence of heterogeneity in the association of IGF-I with bladder cancer risk by tumour aggressiveness, sex, smoking status, or by time between blood collection and diagnosis (pheterogeneity > 0.05 for all). This first prospective study indicates no evidence of an association between plasma IGF-I concentrations and bladder cancer risk.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Travis, Ruth C
|b 1
700 1 _ |a Appleby, Paul N
|b 2
700 1 _ |a Tipper, Sarah
|b 3
700 1 _ |a Weiderpass, Elisabete
|b 4
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 5
|u dkfz
700 1 _ |a Gram, Inger T
|b 6
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 7
|u dkfz
700 1 _ |a Kiemeney, Lambertus A
|b 8
700 1 _ |a Ljungberg, Börje
|b 9
700 1 _ |a Tumino, Rosario
|b 10
700 1 _ |a Tjønneland, Anne
|b 11
700 1 _ |a Roswall, Nina
|0 0000-0003-3071-1658
|b 12
700 1 _ |a Overvad, Kim
|b 13
700 1 _ |a Boutron-Ruault, Marie-Christine
|b 14
700 1 _ |a Manciniveri, Francesca Romana
|b 15
700 1 _ |a Severi, Gianluca
|b 16
700 1 _ |a Trichopoulou, Antonia
|b 17
700 1 _ |a Masala, Giovanna
|0 0000-0002-5758-9069
|b 18
700 1 _ |a Sacerdote, Carlotta
|0 0000-0002-8008-5096
|b 19
700 1 _ |a Agnoli, Claudia
|b 20
700 1 _ |a Panico, Salvatore
|b 21
700 1 _ |a Bueno-de-Mesquita, Bas
|b 22
700 1 _ |a Peeters, Petra H
|b 23
700 1 _ |a Salamanca-Fernández, Elena
|b 24
700 1 _ |a Chirlaque, Maria-Dolores
|b 25
700 1 _ |a Ardanaz, Eva
|b 26
700 1 _ |a Dorronsoro, Miren
|b 27
700 1 _ |a Menéndez, Virginia
|b 28
700 1 _ |a Luján-Barroso, Leila
|b 29
700 1 _ |a Liedberg, Fredrik
|b 30
700 1 _ |a Freisling, Heinz
|b 31
700 1 _ |a Gunter, Marc
|b 32
700 1 _ |a Aune, Dagfinn
|b 33
700 1 _ |a Cross, Amanda J
|b 34
700 1 _ |a Riboli, Elio
|b 35
700 1 _ |a Key, Timothy J
|b 36
700 1 _ |a Perez-Cornago, Aurora
|0 0000-0002-5652-356X
|b 37
773 _ _ |a 10.1002/ijc.31650
|g Vol. 143, no. 10, p. 2351 - 2358
|0 PERI:(DE-600)1474822-8
|n 10
|p 2351 - 2358
|t International journal of cancer
|v 143
|y 2018
|x 0020-7136
909 C O |o oai:inrepo02.dkfz.de:141418
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2017
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebserkrankungen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21